Short regimen of praziquantel in the treatment of single brain enhancing lesions

E. Javier Pretell, Héctor H. Garcia, Nilton Custodio, Carmen Padilla, Manuel Alvarado, Robert H. Gilman, Manuel Martinez

Research output: Contribution to journalArticle

Abstract

Twenty-six patients with single enhancing brain lesion (SEL) were openly assigned to receive single-day praziquantel therapy (n=14), or not (n=12). From 14 treated patients, complete resolution was found in 11, partial resolution in two, and the remaining case was later diagnosed as an arteriovenous malformation. Side effects presented in only one patient and remitted in the same day with symptomatic treatment. Conversely, the lesions persisted unchanged in six of 12 patients in the non-treatment group. Untreated patients with persisting lesions were prescribed praziquantel treatment. After this, SELs disappeared in three cases, other diagnoses (brain tuberculoma and arteriovenous malformation) were made in two, and one was not evaluated. When analyzed in regard to the baseline serology, resolution of lesions on computed tomography was found in 13 (complete=12, partial=1) of 14 seropositive patients, whereas it only happened in six (complete=5, partial=1) of 12 seronegative patients. Serological screening defines a subset of SEL patients with good prognosis. If antiparasitic therapy is to be used in patients with SEL, and we cannot find a strong argument against it, single-day praziquantel is the regimen of choice based on duration, costs, and minimal side effects.

Original languageEnglish (US)
Pages (from-to)215-218
Number of pages4
JournalClinical Neurology and Neurosurgery
Volume102
Issue number4
DOIs
StatePublished - Dec 1 2000

Keywords

  • Cysticercosis
  • Enhancing lesions
  • Praziquantel
  • Taenia solium

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Short regimen of praziquantel in the treatment of single brain enhancing lesions'. Together they form a unique fingerprint.

  • Cite this